Dual FDA Advisory Committee Reviews Shaping Up To Be A Showdown For Dueling Merck And Vertex Hepatitis C Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
Approval is widely assumed for both boceprevir and telaprevir, but there is still much to be discussed about the devilish details. Additional data coming out at European liver meeting should also be informative.
You may also be interested in...
Merck's Victrelis Beats Vertex's Incivek To Lucrative EU HepC Market
Victrelis' final European approval means that Merck & Co. has its nose in front of rival Vertex for the time being.
Merck's Victrelis Beats Vertex's Incivek To Lucrative EU HepC Market
Victrelis' final European approval means that Merck & Co. has its nose in front of rival Vertex for the time being.
Merck To Ship Hepatitis C Drug Victrelis To Pharmacies Within A Week
Merck will begin shipping Victrelis (boceprevir) to pharmacies within a week, the company announced following FDA approval of the hepatitis C drug after market-close on May 13 – a time-frame that roughly coincides with expected FDA action on Vertex's Incivek (telaprevir).